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Articles
Trends in antimicrobial resistance in bloodstream infection 
isolates at a large urban hospital in Malawi (1998–2016): 
a surveillance study
Patrick Musicha, Jennifer E Cornick, Naor Bar-Zeev, Neil French, Clemens Masesa, Brigitte Denis, Neil Kennedy, Jane Mallewa, Melita A Gordon, 
Chisomo L Msefula, Robert S Heyderman, Dean B Everett, Nicholas A Feasey
Summary
Background Bacterial bloodstream infection is a common cause of morbidity and mortality in sub-Saharan Africa, yet 
few facilities are able to maintain long-term surveillance. The Malawi-Liverpool-Wellcome Trust Clinical Research 
Programme has done sentinel surveillance of bacteraemia since 1998. We report long-term trends in bloodstream 
infection and antimicrobial resistance from this surveillance.
Methods In this surveillance study, we analysed blood cultures that were routinely taken from adult and paediatric 
patients with fever or suspicion of sepsis admitted to Queen Elizabeth Central Hospital, Blantyre, Malawi from 1998 
to 2016. The hospital served an urban population of 920 000 in 2016, with 1000 beds, although occupancy often exceeds 
capacity. The hospital admits about 10 000 adults and 30 000 children each year. Antimicrobial susceptibility tests were 
done by the disc diffusion method according to British Society of Antimicrobial Chemotherapy guidelines. We used 
the Cochran-Armitage test for trend to examine trends in rates of antimicrobial resistance, and negative binomial 
regression to examine trends in icidence of bloodstream infection over time.
Findings Between Jan 1, 1998, and Dec 31, 2016, we isolated 29 183 pathogens from 194 539 blood cultures. Pathogen 
detection decreased significantly from 327·1/100 000 in 1998 to 120·2/100 000 in 2016 (p<0·0001). 13 366 (51·1%) of 
26 174 bacterial isolates were resistant to the Malawian first-line antibiotics amoxicillin or penicillin, chloramphenicol, 
and co-trimoxazole; 68·3% of Gram-negative and 6·6% of Gram-positive pathogens. The proportions of non-
Salmonella Enterobacteriaceae with extended spectrum beta-lactamase (ESBL) or fluoroquinolone resistance rose 
significantly after 2003 to 61·9% in 2016 (p<0·0001). Between 2003 and 2016, ESBL resistance rose from 0·7% to 
30·3% in Escherichia coli, from 11·8% to 90·5% in Klebsiella spp and from 30·4% to 71·9% in other Enterobacteriaceae. 
Similarly, resistance to ciprofloxacin rose from 2·5% to 31·1% in E coli, from 1·7% to 70·2% in Klebsiella spp and 
from 5·9% to 68·8% in other Enterobacteriaceae. By contrast, more than 92·0% of common Gram-positive pathogens 
remain susceptible to either penicillin or chloramphenicol. Meticillin-resistant Staphylococcus aureus (MRSA) was 
first reported in 1998 at 7·7% and represented 18·4% of S aureus isolates in 2016.
Interpretation The rapid expansion of ESBL and fluoroquinolone resistance among common Gram-negative 
pathogens, and the emergence of MRSA, highlight the growing challenge of bloodstream infections that are effectively 
impossible to treat in this resource-limited setting. 
Funding Wellcome Trust, H3ABionet, Southern Africa Consortium for Research Excellence (SACORE).
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Bloodstream infection is a leading cause of morbidity and 
mortality in both adults and children in sub-Saharan 
Africa.1 In this region, the high burden of bacterial 
bloodstream infection has been strongly associated with 
the high prevalence of HIV, malaria, and malnutrition.1–4 
The clinical effect of bloodstream infections in sub-Saharan 
Africa is exacerbated by the inadequacy of diagnostic 
facilities, precluding both timely diagnosis of severe 
bacterial infection and implementation of appropriate 
antimicrobial therapy.5
Since 1998, sentinel bacteraemia surveillance has been 
done at Queen Elizabeth Central Hospital (QECH), 
Blantyre, Malawi, a setting with a high prevalence of HIV, 
malaria, and malnutrition.6 Blantyre is one of two principal 
cities in Malawi and the population of its urban and 
peri-urban rural areas expanded rapidly during the study 
period. QECH is one of the largest government hospitals in 
Malawi and is the only public hospital providing free 
medical care to Blantyre city, serving an urban population 
of 920 000 in 2016. The hospital has about 1000 beds, 
although occupancy frequently exceeds capacity. The 
hospital admits about 10 000 adults (aged 16 years or older) 
and 30 000 children (aged younger than 16 years) per year. 
From 1998 to 2015, sepsis was treated either with 
chloramphenicol and benzylpenicillin, or with ceftriaxone, 
which was introduced in Malawi in 2004. Ceftriaxone was 
not widely available in the city or district of Blantyre outside 
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of QECH; however, it was extensively used as a first-line 
agent at QECH and was given to 90·0% of febrile adult 
patients admitted to QECH in one study in 2009–10.7 
During this same period, antiretroviral therapy 
(ART) programmes, malaria control interventions, and 
improvements in food security and community 
management of malnutrition were rolled out. HIV 
prevalence in Blantyre decreased from 22·3% in 2004, to 
17·6% in 2016, while enrolment on the ART programme in 
Malawi increased from 4000 (2·3% of those in need of 
ART) in 2004, to more than 530 000 (67·0% those in need 
of ART) in 2014.8–11 Conjugate vaccines have been introduced 
against Haemophilus influenzae type b (in 2002) and 
pneumococcus (in 2011).12–14 Over the period of bloodstream 
infection surveillance, there were also considerable 
reductions in mortality among children younger than 
5 years and among HIV-infected adults.7,15,16
Non-typhoidal salmonellae, Salmonella enterica serotype 
Typhi, and Streptococcus pneumoniae were previously 
identified as leading causes of bloodstream infection.6,17,18 
Widespread multidrug-resistant non-typhoidal salmonella 
necessitated the introduction and increasingly extensive 
use of ciprofloxacin (in 2002) and ceftriaxone (in 2004) for 
the management of sepsis.17,19 Extended spectrum beta-
lactamase (ESBL)-producing and fluoroquinolone-resistant 
Enterobacteriaceae have been reported in different 
settings worldwide where cephalosporins and fluoro- 
quinolones have been in use,20–24 including Blantyre, where 
ESBL-producing and fluoroquinolone-resistant Escherichia 
coli, klebsiella, and salmonella isolates have been identified 
previously;7,25,26 however, the full burden of ESBL 
and fluoroquinolone resistance among Gram-negative 
pathogens in this setting has yet to be described.
Among Gram-positive pathogens, we have previously 
reported fluctuating levels of pneumococcal resistance to 
penicillin in Malawi, ranging from 9·0 to 18·0%,18 as was 
also reported in other African settings, such as Senegal.27 
Few studies in sub-Saharan Africa have described the 
prevalence of meticillin-resistant Staphylococcus aureus 
(MRSA) and although MRSA has spread in Malawi, its 
prevalence remains unknown.28
Surveillance data about both long-term bacteraemia 
and antimicrobial resistance are scarce in sub-Saharan 
Africa. We used our comprehensive sentinel surveillance 
dataset to describe longitudinal trends in bloodstream 
infection and antimicrobial resistance over 19 years 
at a large teaching hospital in Blantyre, Malawi, 
with particular focus on prevalence of ESBL and 
fluoroquinolone resistance among Gram-negative 
pathogens, and the emergence of MRSA.
Research in context
Evidence before this study
Long-term surveillance data describing bloodstream infection 
and antimicrobial resistance in sub-Saharan Africa are scarce. 
A systematic review and meta-analysis of community-acquired 
bloodstream infection in Africa by Reddy and colleagues 
identified only 22 studies over a period of more than 20 years 
(up to June, 2009) and most (13) focused on children. 
Only one study from Egypt and none from sub-Saharan Africa 
reported long-term surveillance data for both children and 
adults, and only 13 studies reported antimicrobial susceptibility 
data. A search of PubMed (using the terms: “Africa” AND 
“community acquired” AND [“bacteraemia” OR “sepsis”]) for 
July, 2009–June, 2016, revealed two large bacteraemia datasets; 
one from South Africa containing 17 001 blood culture results 
from a 6-year period and the other from Mozambique 
containing a further 19 896 blood culture results from a 5-year 
period. These studies reported trends in community-acquired 
bloodstream infection and antimicrobial resistance in all 
pathogens, but only for paediatric patients. We found no 
studies detailing longitudinal passive bloodstream infection 
surveillance from both adults and children.
Added value of this study
Like many sub-Saharan African countries, Malawi is under 
considerable pressure from poverty, undernutrition, 
urbanisation, malaria, and HIV. Blantyre is a major African city, 
grappling with the same issues of rapid expansion in 
population size with insufficient access to water and sanitation 
as elsewhere on the continent. We present the largest 
bacteraemia and antimicrobial resistance surveillance dataset 
yet collected from sub-Saharan Africa and describe trends in 
bloodstream infection in both adults and children presenting to 
a major urban teaching hospital in Malawi over a 
19-year period. Our study reveals a decline in the incidence of 
bloodstream infection caused by all pathogens except 
Salmonella Typhi. This decrease has occurred concurrently with 
several major public health interventions, including the 
extensive roll-out of both antiretroviral therapy and malaria 
control interventions, improvements in food security and the 
community management of malnutrition, and the introduction 
of Haemophilus influenzae type b and pneumococcal conjugate 
vaccines. This good news is tempered by the emergence and 
rapid expansion of drug-resistant pathogens, including 
cephalosporin-resistant and fluoroquinolone-resistant 
Enterobacteriaceae, penicillin-resistant Streptococcus 
pneumoniae and meticillin-resistant Staphylococcus aureus.
Implications of all the available evidence
Although there has been a marked decrease in 
community-acquired bacterial bloodstream infection in 
Malawi, more pathogens are becoming effectively untreatable 
because of their resistance to locally available antimicrobial 
agents. As alternative agents such as carbapenems are 
expensive and currently unavailable in this resource-limited 
setting, actions to help mitigate further spread of resistance to 
the available antimicrobials are urgently needed.
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Methods
Study design and procedures
In this surveillance study, we analysed blood cultures 
that were routinely taken from adult and paediatric 
patients with fever or suspicion of sepsis admitted to 
QECH, Blantyre, Malawi between 1998 and 2016.
The Malawi-Liverpool-Wellcome Trust Clinical 
Research Programme has provided routine, quality 
controlled, diagnostic blood culture service for febrile 
adult and paediatric medical patients admitted to QECH 
since 1998. A recommended 7–10 mL of blood were taken 
for culture under aseptic conditions from all adult 
patients admitted to the hospital with fever (axillary 
temperature >37·5°C) or clinical suspicion of sepsis, 
severe sepsis, or septic shock.29 Sepsis, severe sepsis, or 
septic shock were suspected in patients with tachycardia 
(≥90 beats per minute), hypotension (systolic blood 
pressure <90 mm Hg), tachypnoea (respiratory rate 
>20 per minute), or delirium. 3–10 mL of blood was 
taken from children with non-focal febrile illness who 
tested negative for malaria, who were severely ill with 
suspected sepsis, or who failed initial malaria treatment 
and remained febrile.18 In this busy hospital, afebrile 
patients were unlikely to have blood sampled for culture 
unless critically ill with suspected sepsis. If patients were 
critically ill and sample for culture was taken, the patients 
were not excluded from analysis.
Since 2000, blood was inoculated into a single aerobic 
bottle using the automated BacT/ALERT system 
(bioMérieux, France)6 before which, manual culture was 
used.30 Enterobacteriaceae and oxidase-positive Gram-
negative bacilli were identified by API (BioMérieux, 
France), staphylococci by tube coagulase, β-haemolytic 
streptococci by Lancefield antigen testing, and salmonella 
by serotyping according to the White-Kauffmann-Le 
Minor scheme by the polyvalent O & H, O4, O9, Hd, Hg, 
Hi, Hm, and Vi antisera (Pro-Lab Diagnostics, UK). The 
identification of a sample of isolates as Salmonella enterica 
serotype Typhimurium was subsequently substantiated 
by whole genome sequencing and multi-locus sequence 
typing. Haemophilus influenzae was typed using type B 
antisera. Bacteria that form part of the normal skin or oral 
flora, including diphtheroids, bacilli, micrococci, 
coagulase-negative staphylococci, and α-haemolytic 
streptococci (other than S pneumoniae), were considered 
to be contaminants.31
Antimicrobial susceptibility tests were done by the disc 
diffusion method following the British Society of 
Antimicrobial Chemotherapy (BSAC) methods and 
breakpoints. Testing was in most cases limited to one 
plate containing six discs, and the choice of agent varied 
depending on the range of antimicrobials available to 
clinicians. Standard operating procedures are included in 
the appendix. Bacteria were defined as being resistant to 
Malawian first-line drugs (hereafter, RFL) if they were 
resistant to the three first-line antimicrobials commonly 
used in Malawi: amoxicillin, co-trimoxazole, and 
chloramphenicol for Gram-negative isolates; or penicillin, 
co-trimoxazole, and chloramphenicol for Gram-positive 
isolates. Isolates were considered multidrug resistant if 
they were resistant to three or more classes of 
antimicrobials to which reference strains are susceptible.32 
Gram-negative isolates have been screened for ESBL-
producing status using a cefpodoxime disc since 2007. 
Before then, ESBL was inferred on the basis of resistance 
to ceftriaxone. Meticillin resistance in S aureus was 
inferred by cefoxitin resistance, which replaced oxacillin 
resistance testing in 2010.
Statistical analysis
We reported the prevalence of blood culture collection 
and causes of bloodstream infection using frequency 
distributions. Minimum annual incidence rates were 
expressed as incidence per 100 000 age-specific person-
years and estimated by dividing the number of 
bloodstream infections by mid-year population and 
multiplying by 100 000. We used the Cochran-Armitage 
test for trend to examine trends in rates of resistance to 
antimicrobials over time, and negative binomial 
regression to examine trends in incidence of bloodstream 
infection over time. We obtained age-stratified population 
estimates for urban Blantyre for 1998–2007 from the 
1998 National Population Projections and for 2008–16 
from the 2008 National Population Projections by the 
National Statistical Office. Statistical analyses were done 
using R version 3.1.2 for MacOS. Blood culture 
surveillance at QECH was approved by the College of 
Medicine Research Ethics Committee (COMREC) of the 
University of Malawi, approval number P.08/14/1614.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit the paper for 
publication.
Results
Between Jan 1, 1998, and Dec 31, 2016, 194 539 blood 
cultures were collected from adults (79 095 [40·7%]) and 
children (115 444 [59·3%]) presenting to QECH. The 
absolute number of blood cultures collected per year 
fluctuated during the surveillance period (figure 1A). The 
ratio of blood cultures to population size increased up to 
2005, before falling thereafter (figure 1A). 29 183 (15·0%) 
blood cultures yielded pathogens (table 1), a further 
36 763 (18·9%) yielded contaminants (figure 1A; appendix) 
and there was no growth from 128 593 (66·1%) blood 
cultures (figure 1A). The estimated incidence rate of 
bloodstream infection declined substantially during the 
study period from 327·1/100�000 in 1998, to 120·2/100�000 
in 2016 (figure 1A; p<0·0001). The pathogen profiles in 
children and adults are shown in the appendix.
See Online for appendix
For more on the British Society 
of Antimicrobial Chemotherapy 
see http://www.bsac.org.uk
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Trends in salmonella bloodstream infection revealed 
epidemics of non-typhoidal salmonella that peaked 
in 2002, and an epidemic of typhoid fever was described 
in detail up to 2014,6 but are included in table 1 and figure 1 
to place other causes of bloodstream infections in context. 
Our analysis further shows that the S Typhi epidemic has 
been declining since its peak in 2013 (figure 1B). Of 29 183 
bloodstream infections, 2560 (8·8%) were E coli, 
1281 (4·4%) were Klebsiella spp, and 1130 (3·9%) were 
isolates of other species of Enterobacteriaceae. The most 
common other Enterobacteriaceae were Enterobacter spp 
(n=517), Serratia spp (n=211), Citrobacter spp (n=185), 
Proteus spp (n=93), and Shigella spp (n=40; table 1). 
Incidence of bloodstream infection attributable to these 
pathogens significantly declined over time (figure 1B, 1C; 
p<0·0001).
Other Gram-negative causes of bloodstream infection 
included Acinetobacter spp (n=543), Haemophilus spp 
(n=434), Pseudomonas spp (n=442), Neisseria spp (n=210), 
other anaerobes (30), and Vibrio spp (n=12). These together 
were responsible for 1671 (5·7%) of 29 183 positive blood 
cultures (figure 1E).
Trends in S pneumoniae bloodstream infection have 
been described for 2000–09,18 whereas this dataset spans 
1998–2016. In this longer period, 4258 (14·6%) 
of 29 183 bloodstream infections were S pneumoniae 
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Figure 1: Trends in bloodstream infection, 1998–2016
(A) Annual frequency of blood culture sampling, and pathogen and contaminant isolation, plus estimated minimum incidence rates of bloodstream infection. 
(B) Estimated minimum incidence of pathogens isolated at high frequency (≥300/year). (C) Estimated minimum incidence of Gram-negative pathogens isolated at 
intermediate frequency (50–299/year). (D) Estimated minimum incidence of Gram-positive pathogens isolated at intermediate frequency (50–299/year). 
(E) Pathogens isolated at low frequency (<50/year). BSI=bloodstream infections. NTS=non-typhoidal salmonella. 
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isolates. The annual incidence of bloodstream infection 
due to S pneumoniae decreased significantly (figure 1B; 
p<0·0001).
S aureus was the second most common Gram-positive 
cause of bloodstream infection with 1923 (6·6%) of 
29 183 isolates during the study period. Isolation of 
S aureus fluctuated throughout the study period 
(figure 1D), but the incidence of S aureus bloodstream 
infection declined significantly overall (p<0·0001).
1193 (4·5%) of 29 183 bloodstream infections were 
β-haemolytic Streptococcus spp, (including 397 [1·4%] 
group A and 477 [1·6%] group B) and 320 (1·0%) were 
Enterococcus spp (including 220 [0·8%] E faecalis, 76 [0·3%] 
E faecium, and 42 [0·1%] other Enterococcus spp). Whereas 
the incidence of β-haemolytic streptococci declined 
(p=0·0005) during surveillance, there was no significant 
change in enterococcal bloodstream infection (p=0·4900). 
We isolated yeast in 1003 (34%) of 29 183 samples (table 1), 
including 963 isolates of Cryptococcus neoformans 
and 40 of Candida spp. After consistently increasing 
between 1998 and 2006, the incidence of fungus 
bloodstream infection has declined since 2006 (figure 1D).
Of the 29 183 culture-confirmed bloodstream infections, 
the age of the patient was known for 23 219 (79·6%) 
1998–2001 2002–05 2006–09 2010–13 2014–16 Total
Acinetobacter spp 200 (3·0%) 126 (1·0%) 115 (2·0%) 64 (1·5%) 40 (1·0%) 545 (1·9%)
Anaerobes 7 (<0·1%) 8 (<0·1%) 7 (<0·1%) 6 (0·1%) 2 (0·1%) 30 (0·1%)
Citrobacter spp 69 (1·0%) 75 (0·8%) 20 (0·4%) 9 (0·2%) 12 (0·3%) 185 (0·6%)
Escherichia coli 592 (9·0%) 661 (7·0%) 552 (10·0%) 398 (9·3%) 357 (9·3%) 2560 (8·8%)
Enterococcus faecalis 48 (0·7%) 57 (0·6%) 61 (1·1%) 27 (0·6%) 27 (0·7%) 220 (0·8%)
Edwardsiella spp 0 2 (<0·1%) 0 0 0 2 (<0·1%)
Enterobacter 93 (1·3%) 173 (2·0%) 88 (1·6%) 74 (1·7%) 89 (2·3%) 517 (1·8%)
Enterococcus spp 14 (0·2%) 2 (<0·1%) 2 (<0·1%) 64 (1·5%) 69 (1·8%) 151 (0·5%)
Escherichia spp 0 3 (<0·1%) 3 (0·1%) 0 0 6 (<0·1%)
Flavobacteria spp 2 (<0·1%) 2 (<0·1%) 2 (<0·1%) 0 0 6 (<0·1%)
Haemophilus influenzae type b 112 (1·6%) 92 (1·0%) 26 (0·5%) 30 (0·7%) 15 (0·4%) 275 (0·9%)
Haemophilus spp 41 (0·6%) 53 (0·6%) 36 (0·7%) 21 (0·5%) 8 (0·2%) 434 (0·5%)
Hafnia spp 3 (<0·1%) 2 (<0·1%) 1 (<0·1%) 0 0 6 (<0·1%)
Klebsiella spp 449 (7·0%) 248 (3·0%) 211 (4·0%) 190 (4·4%) 183 (4·8%) 1281 (4·4%)
Kluyvera spp 2 (<0·1%) 1 (<0·1%) 2 (<0·1%) 2 (<0·1%) 0 7 (<0·1%)
Morganella morganii 0 3 (<0·1%) 4 (0·1%) 11 (0·3%) 1 (<0·1%) 19 (0·1%)
Mycobacterium 60 (1·0%) 0 0 0 0 60 (0·2%)
Neisseria 78 (1·0%) 27 (<0·1%) 42 (1·0%) 34 (0·8%) 39 (1·0%) 220 (0·8%)
Other Gram-negative cocci 15 (<0·1%) 11 (<0·1%) 11 (0·2%) 1 (<0·1%) 0 38 (0·1%)
Other Gram-negative rods 18 (<0·1%) 45 (1·0%) 41 (1·0%) 55 (1·3%) 7 (0·2%) 166 (0·6%)
Non-typhoidal salmonella 2685 (38·9%) 4432 (50·1%) 2141 (40·2%) 782 (18·3%) 433 (11·3%) 10 473 (35·9%)
Streptococcus spp 115 (1·7%) 113 (1·3%) 55 (1·0%) 46 (1·1%) 57 (1·5%) 386 (1·3%)
Pantoea spp 0 0 0 11 (0·3%) 9 (0·2%) 20 (0·1%)
Proteus spp 47 (0·7%) 9 (0·1%) 12 (0·2%) 7 (0·2%) 18 (0·5%) 93 (0·3%)
Pseudomonas 98 (1·0%) 102 (1·0%) 41 (1·0%) 126 (2·9%) 75 (2·0%) 442 (1·5%)
Raoultella spp 0 0 0 3 (0·1%) 8 (0·2%) 11 (<0·1%)
Streptococcus agalactiae 173 (2·5%) 155 (1·8%) 40 (0·8%) 70 (1·3%) 17 (0·4%) 455 (1·6%)
Staphylococcus aureus 505 (7·0%) 480 (5·0%) 258 (5·0%) 344 (8·0%) 338 (8·8%) 1925 (6·6%)
Streptococcus pneumoniae 1139 (17·0%) 1476 (17·0%) 1072 (20·0%) 448 (10·5%) 123 (3·2%) 4258 (14·6%)
Group A streptococcus 117 (1·7%) 102 (1·2%) 69 (1·3%) 59 (1·4%) 50 (1·3%) 397 (1·4%)
Salmonella Typhi 67 (1·0%) 49 (1·0%) 70 (1·0%) 1168 (27·3%) 1643 (43·0%) 2997 (10·3%)
Serratia spp 92 (1·3%) 66 (0·7%) 15 (0·3%) 21 (0·5%) 17 (0·4%) 211 (0·7%)
Shigella spp 1 (<0·1%) 9 (0·1%) 18 (0·3%) 6 (0·1%) 6 (0·2%) 40 (0·1%)
Vibrio spp 5 (<0·1%) 2 (<0·1%) 2 (<0·1%) 3 (0·1%) 0 12 (0·0)
Yersinia 2 (<0·1%) 2 (<0·1%) 1 (<0·1%) 2 (<0·1%) 0 7 (0·0)
Candida spp 4 (<0·1%) 6 (0·1%) 4 (0·1%) 13 (0·3%) 13 (0·3%) 40 (0·1%)
Cryptococcus spp 50 (1·0%) 249 (2·8%) 300 (5·6%) 195 (4·6%) 169 (4·4%) 963 (3·3%)
Total 6903 8843 5322 4290 3825 29 183
Data are n (%).
Table 1: Prevalence of significant pathogens, 1998–2016
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samples. 13 002 (56·0%) patients with known age were 
children (<16 years) and 10 217 (44·0%) were adults 
(≥16 years old). 10 059 (77·4%) children were younger 
than 5 years. Most bacterial species had a bimodal age 
distribution, affecting mostly children under 5 years of 
age and adults aged 20–45 years (appendix). The only 
exception was S Typhi, which was most common in 
children younger than 10 years.6 Cryptococcal bloodstream 
infection was most common in adults aged 20–45 years, 
but uncommon in children (appendix).
When the aggregate data were adjusted to produce 
minimum incidence estimates stratified by age, a 
subtly different picture emerged. The incidence rates 
for E coli bloodstream infection were greatest in 
patients aged 70 years or older (up to 54·3/100 000 per 
year) followed by children younger than 5 years 
(37·5/100 000 per year); and for klebsiella bloodstream 
infection, incidence rates were highest in children 
younger than 5 years (29·2/100 000 per year) followed 
by people aged 75–80 years (24·6/100 000 per year). For 
S Typhi, incidence rates were greatest in children 
between 5 and 10 years and for all other bacterial 
pathogens they were greatest in those younger than 
5 years of age (figure 2).
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Figure 2: Estimated minimum incidence rates of bloodstream infection stratified by age
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27 249 (96·7%) of 28 180 confirmed bacterial bloodstream 
infection isolates were tested for susceptibility to at 
least one antimicrobial agent and 25 752 (91·4%) 
of 28 180 bloodstream infection isolates were tested for 
susceptibility to at least three antimicrobial agents. 
13 343 (52·2%) of 25 572 isolates tested for susceptibility to 
at least three agents were RFL, 10 316 (40·3%) of 25 572 
were resistant to one or two first-line agents, and 
2093 (8·2%) of 25 572 were susceptible to all three first-
line agents (figure 3). Overall, proportions of RFL isolates 
increased during the surveillance period (appendix; 
p<0.0001). RFL was markedly more common among 
Gram-negative isolates (12 902 [68·3%] of 18 887) than 
Gram-positive isolates (441 [6·6%] of 6685). 6129 (91·7%) 
of 6685 Gram-positive isolates were susceptible to either 
penicillin or chloramphenicol.
By contrast with the overall trends in RFL isolates, the 
proportion of E coli isolates that were RFL declined 
substantially during the study period (p<0·0001), primarily 
due to a decline in chloramphenicol resistance (figure 3A; 
p<0·0001). Chloramphenicol resistance also declined in 
Klebsiella spp (p<0·0001), but increased in salmonella 
(appendix), while no significant trend was detected in 
other members of the Enterobacteriaceae (figure 3C; 
p=0·2203).
ESBL production was first detected in E coli in 2004 and 
in Klebsiella spp and other Enterobacteriaceae in 2003. 
Both frequency and incidence of ESBL-producing 
isolates have since increased markedly in all non-
salmonella Enterobacteriaceae (figure 4; appendix). In 
addition to the Enterobacteriaceae, most (168 [61·3%] 
of 274) Acinetobacter spp isolates were ESBL producers 
and there was also an increasing trend of ESBL 
Acinetobacter spp isolates (appendix). Ceftazidime was 
not widely available, therefore pseudomonas isolates 
were not routinely tested; however, seven of 
nine pseudomonas isolates tested were resistant to 
ceftazidime.
Ciprofloxacin resistance was first detected in Blantyre in 
acinetobacter isolates (four [2·3%] of 43) in 2001 and in 
E coli (four [2·5%] of 22) and klebsiella (one [1·7%] of 60) 
isolates in 2003. As with ESBL resistance, we observed 
an increasing trend in both the proportion and rate of 
non-salmonella Enterobacteriaceae with resistance to 
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Figure 3: Trends in proportions of isolates resistant to Malawian first-line antimicrobials
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fluoroquinolones (figure 4). 105 (26·7%) of 393 acinetobacter 
isolates and 55 (12·8%) of 344 pseudomonas isolates were 
resistant to ciprofloxacin.
We detected gentamicin resistance in 462 (18·2%) 
of 2536 E coli, 565 (51·9%) of 1265 Klebsiella spp, and 
320 (29·7%) of 1076 other Enterobacteriaceae, with 
substantial increases in proportions of resistant isolates 
over time (figure 4). 210 (40·1%) of 524 acinetobacter and 
140 (33·6%) of 417 pseudomonas isolates were also 
resistant to gentamicin.
Only 37 (0·9%) of 3049 S pneumoniae isolates were 
resistant to all Malawian first-line agents (figure 3D). 
Resistance to co-trimoxazole was common (3780 [92·5%] 
of 4087 isolates). By contrast, only 610 (15·1%) of 
4043 isolates were resistant or intermediate resistant 
to penicillin (falling to 551 [13·6%] of 4043 when 
intermediate resistance was excluded). The overall trend 
in penicillin resistant isolates was not significant 
(p=0·2300) but a marked rise occurred after the 
introduction of the pneumococcal conjugate vaccine 
(PCV13) in 2011 (figure 3D; p<0·0001). 1074 (26·1%) 
of 4111 S pneumoniae isolates were resistant to 
chloramphenicol. Of isolates tested for susceptibility 
to both chloramphenicol and penicillin, 3971 (99·0%) of 
4013 were susceptible to at least one of the two 
antimicrobial agents. 2200 (53·9%) of 4080 S pneumoniae 
isolates were resistant to tetracycline and 92 (2·2%) of 
4107 S pneumoniae isolates were resistant to the macrolide 
erythromycin.
1151 (79·0%) of 1457 S aureus isolates were resistant to 
penicillin, 828 (43·7%) of 1895 were resistant to 
co-trimoxazole, and 452 (23·8%) of 1898 to chloramphenicol. 
107 (9·6%) of 1118 S aureus isolates were MRSA, which was 
first detected in 1998, but was not regularly isolated 
until 2005 (figure 3E). Only 20 of 1681 S aureus isolates 
were tested for susceptibility to ciprofloxacin and none was 
resistant. 206 (11·5%) of 1790 isolates tested were resistant 
to gentamicin.
855 (70·5%) of 1213 β-haemolytic streptococci isolates 
and 229 (70·5%) of 325 enterococci isolates were resistant 
to co-trimoxazole, whereas 176 (15·3%) of 1149 streptococci 
isolates and 108 (61·4%) of 176 Enterococci spp were 
resistant to penicillin and ampicillin. 208 (17·1%) 
of 1143 streptococci and 198 (60·7%) of 326 enterococci 
were resistant to chloramphenicol. Among group A 
streptococci, 14 (3·7%) of 382 were resistant to penicillin; 
however, these isolates were not speciated and we are 
therefore unable to specifically identify the Streptococcus 
pyogenes isolates within this group.
Most Salmonella spp, E coli, klebsiella, and indeed all 
other Enterobacteriaceae were multidrug resistant, as 
were a substantial proportion of S pneumoniae, other 
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streptococci, and enterococci (table 2). Trends in 
multidrug-resistant isolates were increasing in Klebsiella 
spp (p<0·0001) and in other Streptococcus spp and 
Enterococcus spp (p<0·0001). We detected a decline in 
multidrug resistance (p<0·0001) in E coli isolates 
(table 2).
381 Gram-negative isolates were resistant to all 
agents tested, including amoxicillin, co-trimoxazole, 
chloramphenicol, gentamicin, ciprofloxacin, and 
ceftriaxone, rendering them locally untreatable. Of these 
381 isolates, 121 (31·8%) were Klebsiella spp, 68 (17·8%) 
were E coli, 119 (26·0%) were various other 
Enterobacteriaceae, and 119 (31·2%) were acinetobacter 
(figure 4D). The number of isolates expressing resistance 
to all the six agents was 81 (7·3%) of 1106 bloodstream 
infections in 2016, increased from two (<0·1%) of 
2372 bloodstream isolates in 2003 (figure 4D).
Discussion
Long-term sentinel surveillance in Malawi shows a 
marked decline in the incidence of bloodstream infection 
caused by all pathogens from 1998 to 2016. However, 
concurrent with the declining incidence has been an 
increase in the prevalence of antimicrobial resistance—
including resistance to reserve antimicrobials. These 
changes occurred against a background of improvements 
in food security, malaria control interventions, and highly 
successful roll-out of antiretroviral therapy. Following the 
emergence of widespread resistance to commonly 
available first-line antimicrobial agents, cephalosporins 
and fluoroquinolones have become the drugs of choice 
for treatment of severe bacterial infections in sub-
Saharan Africa.33 The emergence and spread of ESBL-
resistance and fluoroquinolone resistance is therefore a 
major concern in this setting. The prevalences of ESBL 
resistance and fluoroquinolone resistance in E coli and 
klebsiella spp were high, for Africa and when 
considered worldwide.34–36 In other settings, ESBL and 
fluoroquinolone-resistant pathogens are more common 
in hospital-acquired infections than in community-
acquired infections; this study deals with only 
community-acquired bacteraemia. Therefore, the 
findings in this study might underestimate the overall 
rates of ESBL resistance in this setting.37,38
Our findings suggest that the incidence of E coli and 
klebsiella bloodstream infections is highest in elderly 
patients, consistent with global data.39 The Malawi 
National Statistical Office estimates that life expectancy 
in Blantyre will increase from about 55 years in 2007, to 
about 70 years by 2030. Increased life expectancy might 
increase the pool of people at risk of E coli and Klebsiella 
bloodstream infections, with the attendant increasing 
risk of drug resistance.
Resistance to first-line antimicrobials has fluctuated. 
In some Enterobacteriaceae such as E coli and Klebsiella 
spp, RFL rates have begun to decline, primarily due to 
less chloramphenicol resistance. However, the molecular 
determinants of this observation in E coli and 
Escherichia coli Klebsiella spp Enterobacteriaceae Streptococcus 
pneumoniae
Enterococcus spp Streptococcus spp
1998 111/185 (60%) 66/146 (45%) 22/30 (73%) 85/335 (25%) 18/26 (69·%) 18/90 (20%)
1999 118/150 (79%) 31/113 (27%) 12/26 (46%) 98/313 (31%) 8/13 (62%) 15/93 (16%)
2000 83/116 (72%) 38/101 (38%) 60/90 (67%) 80/238 (34%) 3/8 (38%) 21/143 (15%)
2001 96/124 (77%) 17/73 (23%) 87/131 (66%) 41/154 (27%) 10/15 (67%) 13/70 (19%)
2002 113/147 (77%) 20/81 (25%) 64/80 (80%) 75/231 (33%) 2/7 (29%) 8/72 (11%)
2003 110/152 (72%) 24/52 (46%) 67/108 (62%) 116/316 (37%) 2/3 (67%) 13/74 (18%)
2004 92/133 (69%) 21/46 (46%) 39/62 (63%) 83/265 (31%) 5/7 (71%) 22/79 (28%)
2005 121/181 (67%) 22/46 (48%) 24/55 (44%) 158/494 (32%) 32/41 (78%) 28/114 (25%)
2006 84/186 (45%) 18/52 (35%) 45/76 (59%) 110/413 (27%) 6/13 (46%) 15/70 (21%)
2007 81/136 (60%) 27/57 (47%) 15/31 (48%) 105/320 (33%) 9/14 (64%) 10/46 (22%)
2008 81/116 (70%) 36/55 (66%) 10/27 (37%) 54/160 (34%) 12/14 (86%) 6/29 (21%)
2009 60/106 (57%) 29/40 (73%) 12/22 (55%) 47/151 (31%) 12/17 (71%) 4/16 (25%)
2010 64/96 (67%) 34/45 (76%) 25/34 (74%) 34/119 (29%) 10/13 (77%) 13/28 (46%)
2011 76/109 (70%) 35/48 (73%) 10/15 (67%) 71/177 (40%) 6/7 (86%) 28/71 (39%)
2012 42/86 (49%) 32/38 (84%) 17/27 (63%) 30/106 (28%) 15/16 (94%) 7/41 (17%)
2013 74/100 (74%) 33/55 (60%) 42/61 (69%) 12/41 (29%) 15/17 (88%) 25/58 (43%)
2014 63/105 (60%) 41/51 (80%) 40/57 (70%) 12/31 (39%) 15/18 (83%) 16/53 (30%)
2015 65/118 ( 55%) 39/48 (81%) 10/33 (30%) 25/50 (50%) 29/34 (85%) 19/46 (40%)
2016 92/133 (69%) 77/84 (92%) 51/65 (79%) 9/42 (21%) 37/48 (77%) 8/31 (26%)
Overall 1626/2479 (66%) 640/1231 (52%) 652/932 (63%) 1245/3956 (32%) 246/331 (74%) 289/1224 (24%)
p value <0·0001* <0·0001† 0·747 0·148 <0·0001† <0·0001†
†Increasing trend. Isolates are considered multidrug resistant when resistant to at least three antimicrobial classes. *Decreasing trend.
Table 2: Trends in multidrug-resistant bacterial bloodstream infection pathogens in Blantyre, 1998–2016
For National Statistical Office 
of Malawi see http://www.
nsomalawi.mw
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Klebsiella spp are unknown. This partial re-emergence of 
chloramphenicol susceptibility is not sufficiently great to 
permit its reintroduction as an empirical treatment for 
sepsis in Blantyre because of widespread resistance 
among salmonella, the dominant Gram-negative 
pathogens.
Chloramphenicol and penicillin have been commonly 
used in combination for the empirical management of 
sepsis in Malawi for many years.18 99·0% of the 
S pneumoniae isolates are still susceptible to this 
combination despite its wide usage. However, penicillin 
resistance has started to increase since the introduction 
of PCV13 in 2011. PCV13 introduction has been 
associated with a general decline in penicillin-resistant 
S pneumoniae in South Africa.40 However, increasing 
prevalence of penicillin-resistant S pneumoniae serotype 
19F and non-vaccine serotypes such as 19A and 15A have 
been reported following the introduction of the PCV7 
and PCV13 outside sub-Saharan Africa.41,42 The increase 
in the proportion S pneumoniae that are resistant to 
penicillin when S pneumoniae bloodstream infections are 
decreasing raises the possibility that there has been a 
change in serotype distribution following vaccine 
introduction as has been the case in the other settings.41,42
We also describe the emergence of MRSA, although it 
remains an infrequent cause of bloodstream infection in 
Blantyre. The prevalence of MRSA among the S aureus 
isolates was similar to proportions from countries such as 
Mozambique and Zimbabwe, but much lower than those 
reported in South Africa.43–45 This difference might be 
because our cultures were taken from community 
admissions to medical wards; we have yet to study 
nosocomial infection in-depth in our setting. It might also 
be because, unlike in South Africa, medical devices that 
place patients at risk of MRSA bloodstream infection 
(such as central venous catheters) are rarely used in low-
income countries such as Malawi. The sustained presence 
of MRSA as a low-level cause of bloodstream infection in 
Blantyre is of considerable concern. Its relative importance 
as a bloodstream infection pathogen could change greatly 
if surveillance expands to cover surgical patients or 
nosocomial infections or if medical practice changes.
This study has several limitations. The median length 
of stay for adult internal medicine inpatients was 5 days, 
and was shorter for children.46 Typically patients at QECH 
undergo blood culture on admission but it was 
uncommon for patients to have follow-up blood culture 
and it is therefore unlikely that our surveillance has 
captured much nosocomial infection. Community-
acquired sepsis could have been missed if people died at 
home or were not referred to hospital, thus we consider 
our rates to be minimum estimates.
An antimicrobial susceptibility profile was described 
for 96·7% of the isolates and reflect British Society of 
Antimicrobial Chemotherapy guidelines at the time. 
Screening for ESBL was not introduced until 2003, and 
as such ESBL-producing pathogens might have been 
circulating undetected before then. ESBL screening by 
cefpodoxime disc testing was not introduced until 2007, 
consequently some isolates might have been falsely 
classified as ESBL-producing before 2007. Cefoxitin 
screening for MRSA replaced meticillin screening in 
2010, although the small increase in sensitivity gained 
will have made minimal difference to the findings.
The overall decreases in bacterial bloodstream infection 
have been accompanied by a rise in antimicrobial 
resistance in all bacterial bloodstream infection 
pathogens at QECH, especially in Gram-negative 
organisms, and the emergence of meticillin resistance in 
S aureus. Ceftriaxone and ciprofloxacin have been 
essential for the management of bacterial bloodstream 
infection in a setting where human immunosuppression 
and bacterial multidrug resistance are common. The 
emergence of ESBL, fluoroquinolone, and gentamicin 
resistance and MRSA highlight the growing challenge of 
bloodstream infections that are impossible to treat in this 
resource-limited setting.
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